Literature DB >> 10764735

Mechanisms for high affinity mannose 6-phosphate ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor.

J C Byrd1, R G MacDonald.   

Abstract

The two mannose 6-phosphate (Man-6-P) binding domains of the insulin-like growth factor II/mannose 6-phosphate receptor (Man-6-P/IGF2R), located in extracytoplasmic repeats 1-3 and 7-9, are capable of binding Man-6-P with low affinity and glycoproteins that contain more than one Man-6-P residue with high affinity. High affinity multivalent ligand binding sites could be formed through two possible mechanisms: the interaction of two Man-6-P binding domains within one Man-6-P/IGF2R molecule or by receptor oligomerization. To discriminate between these mechanisms, truncated FLAG epitope-tagged Man-6-P/IGF2R constructs, containing one or both of the Man-6-P binding domains, were expressed in 293T cells, and characterized for binding of pentamannose phosphate-bovine serum albumin (PMP-BSA), a pseudoglycoprotein bearing multiple Man-6-P residues. A construct containing all 15 repeats of the Man-6-P/IGF2R extracytoplasmic domain bound PMP-BSA with the same affinity as the full-length receptor (K(d) = 0.54 nm) with a curvilinear Scatchard plot. The presence of excess unlabeled PMP-BSA increased the dissociation rate of pre-formed (125)I-PMP-BSA/receptor complexes, suggesting negative cooperativity in multivalent ligand binding and affirming the role of multiple Man-6-P/IGF2R binding domains in forming high affinity binding sites. Truncated receptors containing only one Man-6-P binding domain and mutant receptor constructs, containing an Arg(1325) --> Ala mutation that eliminates binding to the repeats 7-9 binding domain, formed high affinity PMP-BSA binding, but with reduced stoichiometries. Collectively, these observations suggest that alignment of Man-6-P binding domains of separate Man-6-P/IGF2R molecules is responsible for the formation of high affinity Man-6-P binding sites and provide functional evidence for Man-6-P/IGF2R oligomerization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10764735     DOI: 10.1074/jbc.M000010200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer.

Authors:  Jodi L Kreiling; Michelle A Montgomery; Joseph R Wheeler; Jennifer L Kopanic; Christopher M Connelly; Megan E Zavorka; Jenna L Allison; Richard G Macdonald
Journal:  FEBS J       Date:  2012-07-02       Impact factor: 5.542

2.  Identification of the insulin-like growth factor II receptor as a novel receptor for binding and invasion by Listeria monocytogenes.

Authors:  Uta Gasanov; Craig Koina; Kenneth W Beagley; R John Aitken; Philip M Hansbro
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Quantitative assessment of binding affinities for nanoparticles targeted to vulnerable plaque.

Authors:  Tang Tang; Chuqiao Tu; Sarah Y Chow; Kevin H Leung; Siyi Du; Angelique Y Louie
Journal:  Bioconjug Chem       Date:  2015-05-27       Impact factor: 4.774

4.  General Linker Diversification Approach to Bivalent Ligand Assembly: Generation of an Array of Ligands for the Cation-Independent Mannose 6-Phosphate Receptor.

Authors:  Xiang Fei; Megan E Zavorka; Guillaume Malik; Christopher M Connelly; Richard G MacDonald; David B Berkowitz
Journal:  Org Lett       Date:  2017-07-28       Impact factor: 6.005

5.  High-affinity ligand binding by wild-type/mutant heteromeric complexes of the mannose 6-phosphate/insulin-like growth factor II receptor.

Authors:  Michelle A Hartman; Jodi L Kreiling; James C Byrd; Richard G MacDonald
Journal:  FEBS J       Date:  2009-02-19       Impact factor: 5.542

6.  Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Authors:  Maria Ansar; Daniel Serrano; Iason Papademetriou; Tridib Kumar Bhowmick; Silvia Muro
Journal:  ACS Nano       Date:  2013-11-20       Impact factor: 15.881

Review 7.  Insulin-Like Growth Factor-II/Cation-Independent Mannose 6-Phosphate Receptor in Neurodegenerative Diseases.

Authors:  Y Wang; R G MacDonald; G Thinakaran; S Kar
Journal:  Mol Neurobiol       Date:  2016-03-19       Impact factor: 5.590

8.  A set of phosphatase-inert "molecular rulers" to probe for bivalent mannose 6-phosphate ligand-receptor interactions.

Authors:  Xiang Fei; Christopher M Connelly; Richard G MacDonald; David B Berkowitz
Journal:  Bioorg Med Chem Lett       Date:  2007-11-28       Impact factor: 2.823

9.  Quantitative analysis of insulin-like growth factor 2 receptor and insulin-like growth factor binding proteins to identify control mechanisms for insulin-like growth factor 1 receptor phosphorylation.

Authors:  Dan Tian; Isaiah Mitchell; Pamela K Kreeger
Journal:  BMC Syst Biol       Date:  2016-02-09

10.  Inhibition of insulin-like growth factor II (IGF-II)-dependent cell growth by multidentate pentamannosyl 6-phosphate-based ligands targeting the mannose 6-phosphate/IGF-II receptor.

Authors:  Megan E Zavorka; Christopher M Connelly; Rosslyn Grosely; Richard G MacDonald
Journal:  Oncotarget       Date:  2016-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.